Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.341 SEK | +7.91% | -15.17% | -61.25% |
04-09 | Biosergen to Issue New Units as Compensation Under Rights Issue | MT |
03-27 | Biosergen Raises SEK26.4 Million via Rights Issue | MT |
Sales 2024 * | - | Sales 2025 * | 257M 23.52M 1.88B | Capitalization | 48.55M 4.44M 355M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net Debt 2024 * | 63.1M 5.77M 462M | Net Debt 2025 * | 288M 26.31M 2.11B | EV / Sales 2025 * | 1.31 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 3 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.89% |
1 day | +7.91% | ||
1 week | -15.17% | ||
Current month | -22.85% | ||
1 month | -23.20% | ||
3 months | -50.94% | ||
6 months | -70.35% | ||
Current year | -61.25% |
Managers | Title | Age | Since |
---|---|---|---|
Tine Kold Olesen
CEO | Chief Executive Officer | - | - |
Niels Laursen
DFI | Director of Finance/CFO | 68 | - |
Peder Andersen
CTO | Chief Tech/Sci/R&D Officer | 72 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 31/12/20 | |
Achim Kaufhold
BRD | Director/Board Member | 66 | 31/12/20 |
Chairman | 65 | 31/12/14 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.341 | +7.91% | 3,825 |
25/04/24 | 0.316 | -9.46% | 91,320 |
24/04/24 | 0.349 | -9.82% | 52,874 |
23/04/24 | 0.387 | +12.50% | 93,835 |
22/04/24 | 0.344 | -14.43% | 397,958 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 03:30 pm
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-61.25% | 4.43M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BIOSGN Stock